Syapse announced that it has entered into a research collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will leverage real-world data to drive high-quality insights that will impact patient care and advance oncology research. Under the collaboration, Merck will leverage Syapse’s proprietary RWD platform. Grounded in deep community health system data, Syapse’s platform brings together a multitude of sources, leveraging artificial intelligence and natural language processing to accelerate the capture of typically unstructured data elements, while verifying reliability of the outputs against a source of truth. Industry collaborations that bring to bear expertise in RWE, insights application, clinical care and life science innovation, such as the partnership between Merck and Syapse, will be pivotal in advancing cancer care overall. Bringing together stakeholders from the entire oncology research, development and clinical spectrum, the Syapse Learning Health Network enables improved cancer care through collaboration. Healthcare providers can learn which cancer treatments produced the best real-world outcomes in clinically and molecularly similar patients. Further, researchers can learn from real-world clinical, molecular, treatment and outcomes data. These collaborations are enabled by a secure platform of shared de-identified data that is standardized and normalized across the Syapse Learning Health Network.